Today the BC Cancer Foundation announced a world-leading philanthropic investment of $15.3 million from the Leon Judah Blackmore Foundation to advance lung cancer research and care. Lung cancer is the leading cause of cancer related deaths in B.C. and across Canada. On average, there are 3,400 new cases of lung cancer every year in the province with almost half diagnosed at Stage 4.
With a growing number of effective treatment options available for metastatic prostate cancer now available, there is a need to determine an approach which would more easily identify which treatment option would be most beneficial for each individual patient.
A made-in-Canada approach to producing the world’s most commonly used medical isotope has received Health Canada approval, ushering in a new era for patients in Canada and around the world who rely on these isotopes for critical diagnostic procedures.
Fifteen BC Cancer clinicians and scientists have been named in Clarivate’s Highly Cited Researchers 2020 list announced last week. Each has been ranked in the top one per cent in their fields using a method of data and analysis performed by bibliometric experts and data scientists at the Institute for Scientific Information at Clarivate.
For BC Cancer, those fields include clinical medicine, molecular biology and genetics, and cross-field a category which recognizes influence across several fields.
Reading cancer imaging tests may become more straightforward and informative for BC Cancer radiologists thanks to a new research partnership between BC Cancer and Microsoft’s AI for Health program. In this partnership, a group of data and computer scientists at Microsoft will be working alongside Dr. Arman Rahmim, senior scientist at the BC Cancer Research Institute (BCCRI), and Dr. Ivan Klyuzhin, research programmer at BCCRI. Together the team will be developing AI algorithms to assist radiologists and cancer researchers in detection and assessment of tumours in PET/CT images.
Approximately 835 people in British Columbia will be diagnosed with pancreatic cancer this year. While pancreatic cancer remains one of the most deadly cancers, new research recently published in Cell Reports Medicine has identified a new combination treatment that may overcome drug resistance in pancreatic cancer.
BC Cancer Foundation is the fundraising partner of BC Cancer, which includes BC Cancer Research. Together with our donors, we are changing cancer outcomes for British Columbians by funding innovative research and personalized treatment and care.